Figure1
9
Figure1 HER2 SK Br3 PC3 A
description
A. HER2. PC3. SKBr3. Figure1. % of control. 120 100 80 60 40 20 0. 0 0.03 0.3 3 30 (µM). % of control. 120 100 80 60 40 20 0. 0 0.03 0.3 3 30 (µM). PC3 cells. SKBr3 cells. B. C. % of control. 120 100 80 60 40 20 0. Peptidimer-c. - PowerPoint PPT Presentation
Transcript of Figure1
Figure1
HER2SK
Br3
PC3
A
SKBr3 cells
Figure1
0
20
40
60
80
100
120
0 0.03 0.3 3 300 0.03 0.3 3 30 (µM)
120
100
80
60
40
20
0
Penetratin control
% of control
0
20
40
60
80
100
120
0 0.03 0.3 3 300 0.03 0.3 3 30 (µM)
120
100
80
60
40
20
0
Peptidimer-c
% of control
0
20
40
60
80
100
120
0 0,03 0,3 3 30
120
100
80
60
40
20
00 0.03 0.3 3 30 (µM)
% of control
0
20
40
60
80
100
120
0 0,03 0,3 3 30
120
100
80
60
40
20
00 0.03 0.3 3 30 (µM)
% of control
PC3 cells
Irrelevant peptide
0 1 3 10 30(µM)
120
100
80
60
40
20
00
20
40
60
80
100
120
0 1 3 10 30
B C
D
E
F
A
C
Figure 2
% o
f co
loni
es/c
ontr
ol v
alue
% o
f co
loni
es/c
ontr
ol v
alue
D
Untreated cells
Peptidimer-c0.03µM
Docetaxel0.03nM
Peptidimer-c0.03µM + Docetaxel 0.03nM
Docetaxel 0.03nM + vector 0.03µM
B
Untreated cells
Peptidimer-c0.03µM
Docetaxel0.03nM
Peptidimer-c0.03µM + Docetaxel 0.03nM
Docetaxel 0.03nM + vector 0.03µM
SKBr3 cells
PC3 cellsPC3 cells
SKBr3 cells
020406080
100120
0 0.03 0.3
docetaxel concentration nM
% o
f col
onie
s / c
ontro
l va
lue
docetaxel
docetaxel + peptidimer-c 0.03µM
docetaxel + peptidimer-c 0.3µM
docetaxel+ penetratin vector0.3 µM
0
20
40
60
80
100
120
0.03 0.1 0.3 1 3
docetaxel concentration nM
% o
f co
lon
ie /
con
tro
l va
lue
docetaxel
docetaxel +peptidimer-c 0.03 µM
docetaxel +peptidimer-c 0.3 µM
docetaxel +penetratin vector 0.3µM
C P D P+D V+D V
p44p42
Figure 3
C: controlP: peptidimer-cD: docetaxelV: Vector
Total AKT
Total ERK ½ p44p42
Total Shc
Actin
Phospho-AKT
Phospho-ERK 1/2
Phospho-Shc
Seed cells peptidimer-c 30µM
Days
docetaxel 10nM
LysisDocetaxel 24hPeptidimer-c 48h
D1 D2 D3 D4 D5
0
20
40
60
80
100
120
140
160
180
200
1 2 3 4 5
p-Shc
200
100
0
A
B
C
D
E
0
50
100
150
200
250
C P D P+D V+D V
0
20
40
60
80
100
120
C P D P+D V+D V
100
0
80
4060
20
0
20
40
60
80
100
120
C P D P+D V+D V
p44
p42
0
20
40
60
80
100
120
140
C P D P+D V+D V
100
0
80
4060
20
0
20
40
60
80
100
120
140
C P D P+D V+D V
p-AKT
C P D P+ D
PARP 116 kDaCleaved PARP 85 kDa
Figure 4
C: controlP: peptidimer-cD: docetaxel
Actin
Seed of cells peptidimer-c 30µM
Days
docetaxel 10nM
LysisDocetaxel 48hPeptidimer-c 72h
D1 D2 D3 D4 D5 D6
0
20
40
60
80
100
C P D D + P
%cleaved PARP compared to total
Figure 5A
0,0
1,0
2,0
3,0
4,0
5,0
6,0
0 3 6 9 12 15 18 21 24 27 30 33 36 39
Days after beginning of treatment
**
*
*p<0.05
Days after beginning of treatment
Rel
ativ
e tu
mor
vol
ume
0
1
2
3
4
5
6
0,0
1,0
2,0
3,0
4,0
5,0
6,0
0 3 6 9 12 15 18 21 24 27 30 33 36 39
Control
penetratin vector
Peptidimer-c 1.5 mg/kg i.p.
Figure 5B
1 2 3 4
pERK1/2
Actin
Peptidimer-c Penetratin
0
20
40
60
80
100
120
d0 d2 d0 d2
120100
80604020
0
0
20
40
60
80
100
120
d0 d2 d0 d2
p44
p42
% p
ER
K1/
2 / A
ctin
D 0 D 2 D 0 D 2
0
1
2
3
4
5
6
7
1 6 11 16 21 26 31 36
Rel
ativ
e tu
mor
vol
ume
Days after beginning of treatment
Peptidimer-c 1.5 mg/kg i.p.
control
Figure 5C
0
1
2
3
4
5
6
1 4 7 10 13 16 19 22 25 28 31 34 37 40 43 46 49
days
Re
lati
ve
tu
mo
r vo
lum
eR
elat
ive
tum
or v
olum
e
control
Peptidimer-c 1.5 mg/kg i.p.
Docetaxel 20mg/kg i.p.
Peptidimer-c 1.5mg/kg + docetaxel 20mg/kg
Days after beginning of treatment
**
*
*
p<0.05
Docetaxel15mg/kg i.p.
Peptidimer-c 1.5mg/kg + docetaxel 15 mg/kg
*
**
Figure 6
0
1
2
3
4
5
6
![Master Pages Final5 - Physical Measurement …8]Figure1 showstheRieflerclock on display in the NIST museum in Gaithersburg, MD, where a Shortt pen - Figure1. TheRieflerpendulumclock,](https://static.fdocuments.net/doc/165x107/5ad9d2d97f8b9a52528c04d9/master-pages-final5-physical-measurement-8figure1-showstherieflerclock-on.jpg)
